Related references
Note: Only part of the references are listed.Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response
Fernando Scudiero et al.
CARDIOVASCULAR DRUGS AND THERAPY (2023)
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
Francesco Costa et al.
EUROPEAN HEART JOURNAL (2023)
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2022)
Clinical outcome of patients with ST-elevation myocardial infarction and angiographic evidence of coronary artery ectasia
Cesare Baldi et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2022)
Gene Therapy Targeting PCSK9
Julius L. Katzmann et al.
METABOLITES (2022)
Treatment and Outcome of Patients With Coronary Artery Ectasia: Current Evidence and Novel Opportunities for an Old Dilemma
Luca Esposito et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction The PACMAN-AMI Randomized Clinical Trial
Lorenz Raber et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
Marianna Puccini et al.
METABOLITES (2022)
Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction
Paolo Cimaglia et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2022)
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
Michelle L. O'Donoghue et al.
CIRCULATION (2022)
Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes
Angelo Silverio et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2022)
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
Nicola Ferri et al.
PHARMACOLOGICAL RESEARCH (2022)
Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease A Review
Jacob William Groenendyk et al.
JAMA INTERNAL MEDICINE (2022)
A Comprehensive Review of PCSK9 Inhibitors
Caroline Coppinger et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2022)
Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry
Angelo Silverio et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2021)
Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients
Angelo Silverio et al.
BMC CARDIOVASCULAR DISORDERS (2021)
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study
Stephen J. Nicholls et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)
A Critical Review of the Efficacy and Safety of Inclisiran
Jennifer Hardy et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2021)
Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol
Jing Gao et al.
FRONTIERS IN PHYSIOLOGY (2021)
Pleiotropic Effects of PCSK-9 Inhibitors
Marcin Basiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Predictors of Recurrent Ischemic Events in Patients With ST-Segment Elevation Myocardial Infarction
Gennaro Galasso et al.
AMERICAN JOURNAL OF CARDIOLOGY (2021)
Epidemiology of Peripheral Artery Disease and Polyvascular Disease
Aaron W. Aday et al.
CIRCULATION RESEARCH (2021)
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial
Elvin Kedhi et al.
EUROPEAN HEART JOURNAL (2021)
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial
Elvin Kedhi et al.
EUROPEAN HEART JOURNAL (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
Peter R. Sinnaeve et al.
EUROPEAN HEART JOURNAL (2020)
Percutaneous Treatment and Outcomes of Small Coronary Vessels A SCAAR Report
Angelo Silverio et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy
Hiroyuki Omori et al.
JACC-CARDIOVASCULAR IMAGING (2020)
Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period A Placebo-Controlled, Randomized Trial
Thorsten M. Leucker et al.
CIRCULATION (2020)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Xinjian Liu et al.
NATURE (2020)
Mortality From Ischemic Heart Disease Analysis of Data From the World Health Organization and Coronary Artery Disease Risk Factors From NCD Risk Factor Collaboration
Alexandra N. Nowbar et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2019)
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Konstantinos C. Koskinas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
Francesco Paciullo et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
Edward Lee et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review
Eliano P. Navarese et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
Konstantinos C. Koskinas et al.
EUROPEAN HEART JOURNAL (2018)
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany
Winfried Maerz et al.
ATHEROSCLEROSIS (2018)
PCSK9 From Basic Science Discoveries to Clinical Trials
Michael D. Shapiro et al.
CIRCULATION RESEARCH (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Sreeneeranj Kasichayanula et al.
CLINICAL PHARMACOKINETICS (2018)
Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
Angelos D. Karagiannis et al.
CURRENT ATHEROSCLEROSIS REPORTS (2018)
The Evolving Future of PCSK9 Inhibitors
Robert S. Rosenson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Marc P. Bonaca et al.
CIRCULATION (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
John P. Gibbs et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Alirocumab for the treatment of hypercholesterolemia
Brian Tomlinson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials
Giuseppe De Luca et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
Nihar R. Desai et al.
JAMA CARDIOLOGY (2017)
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up
Antonio J. Vallejo-Vaz et al.
CIRCULATION (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor- Inhibition
Lin Zhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Michel Farnier et al.
ATHEROSCLEROSIS (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Alberico L. Catapano et al.
ATHEROSCLEROSIS (2016)
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study
Leslie Cho et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Henry N. Ginsberg et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon
Gioel Gabrio Secco et al.
EUROINTERVENTION (2016)
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Dean J. Kereiakes et al.
AMERICAN HEART JOURNAL (2015)
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study
Lucia Barbieri et al.
ATHEROSCLEROSIS (2015)
Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease
M. Verdoia et al.
DIABETES & METABOLISM (2015)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Christopher P. Cannon et al.
EUROPEAN HEART JOURNAL (2015)
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks
Eli M. Roth et al.
FUTURE CARDIOLOGY (2015)
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
John J. P. Kastelein et al.
CARDIOVASCULAR DRUGS AND THERAPY (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management: A Meta-analysis of Randomized Trials
Monica Verdoia et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
My-Anh Nguyen et al.
JOURNAL OF LIPID RESEARCH (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
Michael J. Koren et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Keith R. Walley et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering
Tracy Mitchell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation
Hagai Tavori et al.
CIRCULATION (2013)
A meta-analytic overview of thrombectomy during primary angioplasty
Giuseppe De Luca et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI
Giuseppe De Luca et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
Meta-Analysis of Randomized Trials of Glycoprotein IIb/IIIa Inhibitors in High-Risk Acute Coronary Syndromes Patients Undergoing Invasive Strategy
Giuseppe De Luca et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population
Giuseppe De Luca et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease 3 Independent Studies and Meta-Analyses
Marianne Benn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Beyond established and novel risk factors - Lifestyle risk factors for cardiovascular disease
Dariush Mozaffarian et al.
CIRCULATION (2008)
Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: A meta-regression analysis of randomized trials
G De Luca et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)